Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
53.51
UNCHANGED
Streaming Delayed Price
Updated: 3:56 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 02, 2021
From
Incyte
Via
Business Wire
A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus
November 02, 2021
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Expert Ratings For Incyte
September 23, 2021
Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:
Via
Benzinga
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas
November 01, 2021
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),...
Via
Benzinga
Exposures
Product Safety
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 01, 2021
From
Incyte
Via
Business Wire
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
November 01, 2021
From
Incyte
Via
Business Wire
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
October 28, 2021
From
Incyte
Via
Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
October 27, 2021
It's much too early to count these companies out.
Via
The Motley Fool
Could This Be the Next Blockbuster Indication for Eli Lilly?
October 21, 2021
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.
Via
The Motley Fool
Exposures
COVID-19
Incyte to Report Third Quarter Financial Results
October 13, 2021
From
Incyte
Via
Business Wire
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
October 02, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Incyte Names New Member to Its Board of Directors
September 28, 2021
From
Incyte
Via
Business Wire
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
September 27, 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...
Via
Benzinga
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
September 23, 2021
Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin...
Via
Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
September 23, 2021
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
September 23, 2021
Deutsche Bank reduced the price target for FedEx Corporation (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
September 22, 2021
The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
September 22, 2021
From
Incyte
Via
Business Wire
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
September 22, 2021
Find out what held these laggards back.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
September 22, 2021
The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.